Posted by ABMN Staff on Apr 28th, 2024
Blueprint Medicines (NASDAQ:BPMC – Get Free Report) had its price target boosted by research analysts at Stifel Nicolaus from $120.00 to $130.00 in a note issued to investors on Friday, Benzinga reports. The brokerage presently...
More of this article »